Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 16/20 | 0.77 |
| ▸ | F2 | P00734 | 4/20 | 0.77 |
| ▸ | KLK1 | P06870 | 4/20 | 0.77 |
| ▸ | TMPRSS15 | P98073 | 14/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314578 | 1.00 | PRSS1 (0.77) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3237626 | 0.94 | PRSS1 (0.75) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3231199 | 0.92 | PRSS1 (0.72) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3231286 | 0.92 | PRSS1 (0.80) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3237777 | 0.91 | PRSS1 (0.67) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3242330 | 0.90 | PRSS1 (0.80) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3238401 | 0.90 | PRSS1 (0.71) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3239670 | 0.89 | PRSS1 (0.73) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL8982104 | 0.89 | PRSS1 (0.70) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3237750 | 0.88 | PRSS1 (0.80) | PRSS1F2KLK1TMPRSS15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671057-B2 | Therapeutic agent for type II diabetes comprising protease-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| US-5622984-A | INHIBITORS OF PHOSPHOLIPASE, VARIOUS PROTEASES | ONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-04-22 | — | — | US | disclosed |
| US-5614555-A | Amidinophenol derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0588655-B1 | Amidinophenol derivatives | ONO PHARMACEUTICAL CO (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5432178-A | Substituted benzoic acid esters; use to prevent or treat inflammatory diseases, allergic diseases, disseminated intravascular coagulation, pancreatitis or multiple organ failure | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-11 | — | — | US | disclosed |
| EP-0588655-A1 | Amidinophenol derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | DPP4, IAPP, DPP7 | PRSS1 25/4885F2 805/4885KLK1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.